PolyPid Secures $320 Million Partnership with Azurity for D-PLEX100 in U.S. and Canada
Roth Capital maintains a Buy rating with a $9 price target despite the post-deal share decline.
Roth Capital maintains a Buy rating with a $9 price target despite the post-deal share decline.
BMO Capital gives Trevi Therapeutics an Outperform rating and $36 target, citing strong potential for Haduvio as a first-in-class treatment for chronic cough in idiopathic pulmonary fibrosis.
Analyst forecasts show Intel and Samsung struggling to close the gap on A16 and N2 technology.
Genuine Parts lowered its 2026 profit outlook amid weaker consumer demand. CEO Will Stengel denied rumors of a rival acquiring its automotive business.
Bitcoin and Coinbase surge after Bessent signals the CLARITY Act is close to passage. White House ethics agreement removes final hurdle ahead of August recess.
The program covers most iPhones, Macs, iPads, and Apple Watches.